Drug-based cancer therapy remains together with ionizing radiation and surgery one of the major cornerstones in cancer treatment. The recent years have revealed an impressive development in cancer therapeutics moving from conventional cytostatic drugs towards targeted therapeutics which opens the possibilities for personalized cancer treatment. Clinical benefit has indeed been shown for these new targeted therapeutics although they in general have failed to demonstrate complete remission of cancer. There is therefore still an unmet need for highly effective and selective drug-based anticancer modalities.

1. PCI with targeted toxins
2. PCI of antibody based therapeutics
3. Biomarkers for targeted therapeutics

Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital – Radiumhospitalet P. O. Box 4953 Nydalen, NO-0424 Oslo, Norway

Phone: +47-22781481 E mail: anette.weyergang@rr-research.no 

Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital – Radiumhospitalet P. O. Box 4953 Nydalen, NO-0424 Oslo, Norway

Phone: +47-22781481 E mail: anette.weyergang@rr-research.no